2018 ACR/ARHP Annual Meeting

October 19-24, 2018. Chicago, IL.

View by Number View by Title View Sessions

View by Date

Abstract Number: 434

Trends in Procedure Type, Patient Characteristics, and Outcomes Among Persons with Knee Osteoarthritis Undergoing Bariatric Surgery, 2005-2014
Abstract Number: 435

Is Frailty Associated with Worse Outcomes after Total Joint Replacements?
Abstract Number: 436

Structural Effects of Intra-Articular Sprifermin in Symptomatic Radiographic Knee Osteoarthritis: A Post-Hoc Analysis of Cartilage Morphology over the 2-Year Treatment-Period of a 5-Year Randomized, Placebo-Controlled, Phase II Study
Abstract Number: 437

Does Reduction in Mechanical Knee Joint Loading Explain the Beneficial Effects of Weight Loss in Overweight or Obese Patients with Knee Osteoarthritis?
Abstract Number: 438

What Characterizes Osteoarthritis: Ultrasound-Detected Inflammation but Not Osteophytes Is More Common in Hand Osteoarthritis Than in Painless Bony Enlargements
Abstract Number: 439

Articular Cartilage from Osteoarthritis Patients Shows Extracellular Matrix Remodeling over the Course of Treatment with Sprifermin (Recombinant human fibroblast growth factor 18)
Abstract Number: 440

Assessing Inappropriate Pain Management in Adults with Hip or Knee Osteoarthritis Treated with Different Opioid Intensity Regimens: Results from a Retrospective Database Analysis
Abstract Number: 441

The Presence of Neuropathic Pain Does Not Influence the Response to Hyaluronic Acid (HA) in Patients with Knee Osteoarthritis but HA Injections Modify Pain Phenotype
Abstract Number: 442

Patient Factors Associated with Gaps in Osteoarthritis Care
Abstract Number: 443

Impact of Intra-Articular Steroid Injection on Bone Marrow Lesions in Osteoarthritis of the Hip: An Assessment Using the Outcome Measures in Rheumatology Hip MRI Inflammation Scoring System
Abstract Number: 444

Trajectories of Sport or Recreational Activities over Eight Years and Associated Factors in Persons at Risk for Knee Osteoarthritis
Abstract Number: 445

Interleukin-1β Inhibition with Canakinumab Associates with Reduced Rates of Total Hip and Knee Replacement (THR/TKR) and Osteoarthritis (OA) Symptoms: Exploratory Results from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS)
Abstract Number: 446

Participation in American Football Is Associated with Increased Risk for Knee Pain and Osteoarthritis: Data from the Osteoarthritis Initiative
Abstract Number: 447

Discriminating between Central & Peripheral Pain Sensitization Using a Slowly Repeated Evoked Pain Protocol
Abstract Number: 448

Tizanidine, a Frequently Used Muscle Relaxant, Is Associated with Severe Hypotension: Role of Cytochrome P450 1A2 Inhibition in Routine Clinical Practice

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].